Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients

• Published in: PloS one Vol. 17; no. 7; p. e0270786
• Main Authors: Nakai, Masato, Suda, Goki, Ogawa, Koji, Yoshida, Sonoe, Hosoda, Shunichi, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Ohara, Masatsugu, Sho, Takuya, Morikawa, Kenichi, Sakamoto, Naoya
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 01-07-2022; Public Library of Science (PLoS)
• Subjects: Ammonia; Antibiotics; Biology and Life Sciences; Cirrhosis; Classification; Clinical medicine; Dementia; Dosage and administration; Drug therapy; Encephalopathy; Evaluation; Hepatic encephalopathy; Hepatology; Hyperammonemia; Interactive computer systems; Laxatives; Liver; Liver cirrhosis; Medical diagnosis; Medicine and Health Sciences; Multivariate analysis; Neuropsychology; Patients; Physical Sciences; Quality of life; Rifaximin; Social Sciences; Tomography; Variables; Japan; United States > US; Europe
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0270786

Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE). However, the usefulness of rifaximin against CHE is not thoroughly investigated in Japanese patients. We aimed to investigate the efficacy of rifaximin against hyperammonemia and CHE in Japan. We observed 102 patients with HE showing hyperammonemia secondary to LC and examined various biochemical and behavioral parameters following rifaximin treatment. CHE was diagnosed when the patients exhibited two or more abnormal neuropsychological test (NPT) scores but did not indicate OHE symptoms. In the 102 cases, a significant therapeutic effect of rifaximin on hyperammonemia was observed from 2 to 48 weeks after starting treatment. Excluding 10 patients diagnosed with OHE upon starting rifaximin treatment, 12 of the 92 remaining patients (11.8%) transitioned to OHE within 1 year. The 1 year cumulative OHE transition rate was 14.5%. Among the 24 patients with CHE diagnosed by the NPT for whom NPT results could be evaluated at 4 and 12 weeks after starting treatment, 10 (41.6%) had recovered from CHE at 12 weeks. When the factors contributing to recovery from CHE were examined by multivariate analysis, an ammonia level <129 μg/dL was a significant factor. Rifaximin was thus significantly effective against both hyperammonemia and CHE in Japanese patients.